Literature DB >> 8119937

Complementation of apolipoprotein B mRNA editing by human liver accompanied by secretion of apolipoprotein B48.

F Giannoni1, D K Bonen, T Funahashi, C Hadjiagapiou, C F Burant, N O Davidson.   

Abstract

Mammalian small intestine secretes a truncated apolipoprotein B (apoB48) species as a result of tissue-specific post-transcriptional RNA editing. The human liver, by contrast, contains only unedited apoB mRNA and secretes only apoB100. We have recently isolated a cDNA clone from rat small intestine which encodes an apoB mRNA editing protein, REPR (Teng, B., Burant, C.F., and Davidson, N.O. (1993) Science 260, 1816-1819). The current study demonstrates that homogenates of Xenopus oocytes expressing REPR confer editing ability upon S100 extracts prepared from human liver when tested on a synthetic apoB RNA template in vitro. Transfection of REPR into HepG2 cells resulted in editing of endogenous apoB mRNA and the appearance of an apoB48-like protein in the media. Extracts prepared from these transfected cells edit mammalian apoB RNA templates when incubated alone and with enhanced efficiency in the presence of chicken intestinal S100 extracts. The results suggest that human liver expresses factor(s) which are critical to apoB mRNA editing and which allow functional complementation of REPR in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8119937

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Acute modulation of the extent of apoB mRNA editing and the relative rates of syntheses of apoB48 and apoB100 in cultured rat hepatocytes by osmotic and other stress stimuli.

Authors:  A McCahill; D J Lankester; B S Park; N T Price; V A Zammit
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor.

Authors:  Christophe Maris; James Masse; Ann Chester; Naveenan Navaratnam; Frédéric H-T Allain
Journal:  RNA       Date:  2005-02       Impact factor: 4.942

Review 3.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

4.  Mouse and other rodent models of C to U RNA editing.

Authors:  Valerie Blanc; Nicholas O Davidson
Journal:  Methods Mol Biol       Date:  2011

5.  Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing.

Authors:  Y Yang; Y Yang; H C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.

Authors:  Debnath Mukhopadhyay; Shrikant Anant; Robert M Lee; Susan Kennedy; David Viskochil; Nicholas O Davidson
Journal:  Am J Hum Genet       Date:  2001-11-27       Impact factor: 11.025

7.  Guide RNA-mRNA chimeras, which are potential RNA editing intermediates, are formed by endonuclease and RNA ligase in a trypanosome mitochondrial extract.

Authors:  L N Rusché; K J Piller; B Sollner-Webb
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

Review 8.  APOBEC-1-mediated RNA editing.

Authors:  Valerie Blanc; Nicholas O Davidson
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Sep-Oct

9.  Molecular cloning of a human small intestinal apolipoprotein B mRNA editing protein.

Authors:  C Hadjiagapiou; F Giannoni; T Funahashi; S F Skarosi; N O Davidson
Journal:  Nucleic Acids Res       Date:  1994-05-25       Impact factor: 16.971

10.  An auxiliary factor containing a 240-kDa protein complex is involved in apolipoprotein B RNA editing.

Authors:  D Schock; S R Kuo; M F Steinburg; M Bolognino; J D Sparks; C E Sparks; H C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.